-
公开(公告)号：US11884610B2
公开(公告)日：2024-01-30
申请号：US17806821
申请日：2022-06-14
发明人： Kristin Patterson , Jiping Liu , Ricky Wayne Couch , Peter Gregory Varlashkin , Mai Li , Yonghong Gan
CPC分类号： C07C259/10 , A61K9/0095 , A61K9/2013 , A61K9/2054 , A61K9/4825 , A61K9/4858 , A61K9/4866 , C07B2200/13
摘要： The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
-
公开(公告)号：US11084780B1
公开(公告)日：2021-08-10
申请号：US17177966
申请日：2021-02-17
发明人： Kristin Patterson , Jiping Liu , Ricky Wayne Couch , Peter Gregory Varlashkin , Mai Li , Yonghong Gan
IPC分类号： A61K31/16 , C07C231/00 , A61P35/00 , C07C259/10 , A61K9/00 , A61K9/20 , A61K9/48
摘要： The present disclosure relates to a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof, and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
-
公开(公告)号：US12029711B1
公开(公告)日：2024-07-09
申请号：US18608735
申请日：2024-03-18
发明人： Piero L. Ruggiero , Kristin Patterson , Mark Hatcher , Jiping Liu , Uchenna H. Iloeje , Abraham J. Langseth
IPC分类号： A61K31/166 , A61K9/00 , A61K9/48
CPC分类号： A61K31/166 , A61K9/0053 , A61K9/4825 , A61K9/4833 , A61K9/4858 , A61K9/4866
摘要： The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
-
公开(公告)号：US11571402B2
公开(公告)日：2023-02-07
申请号：US17177999
申请日：2021-02-17
发明人： Kristin Patterson , Jiping Liu
IPC分类号： A61K31/167 , A61K9/16 , A61K9/20 , A61K9/00
摘要： The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
-
公开(公告)号：US12090128B2
公开(公告)日：2024-09-17
申请号：US18429056
申请日：2024-01-31
发明人： Kristin Patterson , Jiping Liu
IPC分类号： A61K31/167 , A61K9/00 , A61K9/16 , A61K9/20
CPC分类号： A61K31/167 , A61K9/0056 , A61K9/16 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2072
摘要： The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.
-
公开(公告)号：US11427534B1
公开(公告)日：2022-08-30
申请号：US17393144
申请日：2021-08-03
发明人： Kristin Patterson , Jiping Liu , Ricky Wayne Couch , Peter Gregory Varlashkin , Mai Li , Yonghong Gan
摘要： The present disclosure relates to: a) crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, h) pharmaceutical compositions comprising one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, one or more pharmaceutically acceptable carriers; c) methods of treating a tumor a cancer, or a Rasopathy disorder by administering one or more crystalline forms of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof; and methods of producing essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
